BridgeBio Pharma announced that on April 7, 2023, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- UBS sees fair value for BridgeBio pipeline at $36-$40 per share
- Mizuho doubts BridgeBio selling itself, says royalty deal more likely
- BridgeBio canceled conference over ‘conflict,’ Bloomberg reports
- BridgeBio likely worth $3B-$4B in takeover, says BofA
